secwatch.observer — SEC 8-K summary
======================================

Issuer:     CalciMedica, Inc. (CALC)
CIK:        0001534133
Form:       8-K
Filed at:   2026-05-12T11:00:16+00:00
Accession:  0001193125-26-218134
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CalciMedica reports Q1 net income $5.0M; FDA feedback on Auxora pivotal program expected Q2 2026
--------------------------------------------------------------------------------

- Net income $5.0M ($0.31 basic) vs net loss $5.0M a year ago; cash $8.2M as of March 31, 2026.
- R&D expenses $3.5M, G&A $2.1M; other income $10.6M from fair value adjustments on warrants and note.
- FDA feedback on pivotal program design for Auxora in acute pancreatitis expected in Q2 2026.
- IND submission for oral CRAC inhibitor CM5480 in pulmonary hypertension anticipated in 2027.
- Phase 2b CARPO results published: Auxora showed 100% reduction in new-onset severe respiratory failure (p<0.05).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534133/000119312526218134/0001193125-26-218134-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534133/000119312526218134/ck0001534133-20260512.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-218134

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer